Bristol-Myers Squibb (BMY) Tops Q1 EPS by 1c, Maintains EPS Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $1.10, $0.01 better than the analyst estimate of $1.09. Revenue for the quarter came in at $5.92 billion versus the consensus estimate of $5.76 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2019 EPS of $4.10-$4.20, versus the consensus of $4.19.

• Worldwide revenues increasing in the mid-single digits.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates